# Azenta, Inc. (AZTA)

> Source: Nexqual · https://nexqual.com/AZTA · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Azenta, Inc. (AZTA), nexqual.com/AZTA" · informational, not investment advice.

**Price:** USD 41.27 (+1.58% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 40.63 · day 40.46–41.7 · 52w 15.93–46.41 · market cap $1.81B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $614M, net income -$123M (-20.0% margin), free cash flow $9.9M (SEC filings).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $164K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 37.8 (range 33–44).
- Total return with dividends: 1Y +35.9% vs S&P 500 +14.8%; 5Y -64.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-10, EPS estimate USD 0.11, revenue estimate $160M. All companies reporting that day: https://nexqual.com/earnings/2026-11-10
- Dividend: USD 0 paid over the last 12 months; latest ex-dividend date 2021-12-02.
- Short interest: 19.87% of float (as of 2026-10-15), 4.4 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $514M | $555M | $551M | $573M | $594M | $614M |
| Gross profit | $244M | $256M | $239M | $255M | $270M | — |
| Operating income | -$31.1M | -$24.7M | -$61.2M | -$51.3M | -$26.8M | -$175M |
| Net income | $111M | $2.13B | -$14.6M | -$165M | -$55.8M | -$123M |
| EPS (diluted) | $1.49 | $28.48 | -$0.22 | -$3.10 | -$1.22 | — |
| Free cash flow | $97.1M | -$539M | -$33.6M | $12.4M | $38.3M | $9.9M |
| Gross margin | 47.5% | 46.0% | 43.4% | 44.4% | 45.5% | — |
| Operating margin | -6.1% | -4.5% | -11.1% | -8.9% | -4.5% | -28.6% |
| Net margin | 21.6% | 384.0% | -2.7% | -28.8% | -9.4% | -20.0% |
| Revenue growth | +32.2% | +8.1% | -0.7% | +4.0% | +3.6% | — |
| Cash + short-term investments | $228M | $1.57B | $1.10B | $491M | $546M | — |
| Total debt | $49.7M | — | — | — | — | — |
Fiscal years end Sep. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 3.0x · P/FCF 183.0x · P/B 1.2x · FCF yield 0.55% · Earnings yield -6.80%

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $164K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-18 | Cornog William L | Director | 10,000 | $164K | 16.38 | Too little history (no open-market trades in 2023) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 37.8 (low 33, high 44).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | Needham | Reiterated | Buy | $37 |
| 2026-08-06 | Evercore ISI Group | Target raised | Outperform | $28 → $35 |
| 2026-08-05 | Needham | Target raised | Buy | $33 → $37 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +35.9% | -64.5% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +36.1% | -18.7% |
| Volatility (annualized) | 66.1% | 51.4% |
| Max drawdown | -60.9% (Jan 2026→May 2026) | -87.0% (Nov 2021→May 2026) |

## Dividends
Dividend. Paid over the last 12 months: USD 0.00 in 0 payments.
Most recent ex-dividend date: Dec 2, 2021; payment date: Dec 23, 2021. To receive a dividend, shares must be owned before the ex-dividend date.
5-year average yield 1.05%.
| Ex-dividend date | Amount per share |
|---|---|
| 2021-12-02 | USD 0.10 |

## Short interest
5,362,594 shares sold short, 19.87% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 5,382,386 shares (-0.4%). Days to cover: 4.4 (short shares ÷ average daily volume).

## Peers (Medical Instruments & Supplies)
XRAY (DENTSPLY SIRONA Inc.) USD 9.61 +1.80% · LMAT (LeMaitre Vascular, Inc.) USD 85.27 +2.90% · WRBY (Warby Parker Inc.) USD 24.59 +0.65% · ATRC (AtriCure, Inc.) USD 62.48 +1.73% · PLSE (Pulse Biosciences, Inc) USD 55.48 +3.37% · NVST (Envista Holdings Corporation) USD 24.61 +2.80%

## More
Full page: https://nexqual.com/AZTA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-04)

- "Fiscal 2026 Guidance - Continuing Operations • Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is expected to decline approximately in the low single digits relative to the fourth quarter of fiscal 2025. • Adjusted EBITDA is expected to range approximately between $20 million and $23 million."

Analysts expect $160.2M for the current quarter, +645.1% vs the guidance midpoint $21.5M. Source: https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/azta-2026q326erxexx991.htm

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.11 | $0.22 | -48.3% | $160.2M | 6 |
| Next quarter (ends 2026-12-31) | $0.10 | $0.14 | -30.9% | $155.6M | 3 |
| Current fiscal year (ends 2026-09-30) | $0.32 | $0.38 | -15.8% | $614.8M | 6 |
| Next fiscal year (ends 2027-09-30) | $0.53 | $0.61 | -14.3% | $639.3M | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-10): ±12.4%; last 8 reports averaged ±13.1%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 22 | 62.5% | ±12.4% |
| 2026-12-18 | 50 | 55.0% | ±17.8% |
| 2027-01-15 | 78 | 60.0% | ±21.7% |
| 2027-03-19 | 141 | 61.6% | ±29.9% |
| 2027-04-16 | 169 | 59.6% | ±31.6% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | $0.16 | $0.10 | Beat +60.0% | +6.5% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | −$0.04 | $0.14 | Miss −$0.18 | -24.5% |
| Feb 4, 2026 | Quarter ended Dec 31, 2025 | $0.09 | $0.13 | Miss −30.8% | -24.5% |
| Nov 21, 2025 | Quarter ended Sep 30, 2025 | $0.21 | $0.20 | Beat +5.0% | +22.3% |
| Aug 5, 2025 | — | — | — | — | -12.4% |
| May 7, 2025 | — | — | — | — | +9.0% |
| Feb 5, 2025 | — | — | — | — | +4.0% |
| Jan 30, 2025 | — | — | — | — | +1.2% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-07 | 8-K | Exit or restructuring costs (layoffs, closures); Material impairment — “On October 5, 2026, the Board of Directors of Azenta, Inc. (the "Company") approved, and the Company committed to, a restructuring plan (the "Plan") within the Company's Multiomics reportable segment. The Plan is intended primarily to consolidate the Company's North American laboratory network, simplify its organizational structure and improve operating efficiency, and consists of workforce reductions and the closure of three of the Company's Multiomics laboratory sites in North America. The Company began…” | https://www.sec.gov/Archives/edgar/data/933974/000162828026065292/0001628280-26-065292-index.htm |
| 2026-09-17 | 8-K | Director or executive officer change, or pay arrangement — “Interim President and Chief Executive Officer Compensation As previously disclosed in the Company's Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the "Board") of Azenta, Inc. (the "Company") appointed Dr. Martin D. Madaus as the Company's Interim President and Chief Executive Officer, effective August 22, 2026 (the "Start Date"), and the Company was reviewing his compensation in connection with that appointment. On September 14, 2026, upon the recommendation of the Human Resources…” | https://www.sec.gov/Archives/edgar/data/933974/000162828026062474/0001628280-26-062474-index.htm |
| 2026-09-04 | 8-K | Regulation FD disclosure; Other material event — “As previously disclosed in the Company's Current Report on Form 8-K filed on July 8, 2026, on July 1, 2026, in connection with the completion of the sale by Azenta Germany GmbH, a wholly owned subsidiary of the Company, of the entire issued share capital of B Medical Systems S. r.l. ("B Medical") to Thelema S. r.l. ("Thelema"), Azenta Germany GmbH entered into a Vendor Loan Agreement with Thelema (the "Vendor Loan Agreement"), pursuant to which Azenta Germany GmbH provided a secured term loan to Thelema in an…” | https://www.sec.gov/Archives/edgar/data/933974/000162828026060614/0001628280-26-060614-index.htm |
| 2026-08-24 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure — “Resignation of President and Chief Executive Officer On August 22, 2026, John P. Marotta resigned as President and Chief Executive Officer of Azenta, Inc. (the "Company") and as a member of the Company's Board of Directors (the "Board"), effective as of August 22, 2026 (the "Effective Date"). Mr. Marotta's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. In connection with Mr. Marotta's resignation, the Board reduced the…” | https://www.sec.gov/Archives/edgar/data/933974/000162828026058519/0001628280-26-058519-index.htm |
| 2026-08-11 | 8-K | Director or executive officer change, or pay arrangement | https://www.sec.gov/Archives/edgar/data/933974/000162828026055414/0001628280-26-055414-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/933974/000162828026054295/0001628280-26-054295-index.htm |
| 2026-08-04 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/933974/000162828026052642/0001628280-26-052642-index.htm |
| 2026-07-08 | 8-K | Entered a material agreement; Completed an acquisition or sale of assets; Regulation FD disclosure — “On July 1, 2026, in connection with the closing of the Transaction (as defined in Item 2.01 below), Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc. (the "Company"), entered into a Vendor Loan Agreement (the "Vendor Loan Agreement") with Thelema S. r.l. ("Thelema"), pursuant to which Azenta Germany GmbH agreed to provide a secured term loan to Thelema in an aggregate principal amount of $35 million. The Vendor Loan Agreement was entered into to support and facilitate the completion of the…” | https://www.sec.gov/Archives/edgar/data/933974/000162828026047591/0001628280-26-047591-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.